Tesamorelin + Ipamorelin 10
Tesamorelin + Ipamorelin 10 is a research-compound blend of 5 mg tesamorelin (a GHRH analog) and 5 mg ipamorelin (a selective GH secretagogue) in a 10 mg vial — an even split, unlike the 16 mg 13 / 3 vial.
Mixed with 3 mL of bacteriostatic water it is dosed in insulin units: 6 units to start (0.1 mg of each), 12 units (0.2 mg) and 18 units at the top (0.3 mg of each), nightly at bedtime while fasted.
Best for
Growth-hormone-axis research where the ipamorelin dose leads: every rung sits on ipamorelin's own 100 / 200 / 300 mcg range, while tesamorelin stays well below the 1–2 mg used in its trials. Not the vial for someone after a studied tesamorelin dose; because its concentration differs from the 13 and 16 mg vials, their unit numbers do not transfer.
What to expect
Ipamorelin's GH pulse follows each injection within hours. Tesamorelin's visceral-fat effects were measured over 12–26 weeks at 1–2 mg a day — doses this vial does not reach.
Pairs with
Already a two-receptor GH-axis stack (a GHRH analog plus a ghrelin-receptor agonist): adding another GH secretagogue doubles the same pathway, so it is usually run standalone.
Subcutaneous injection nightly at bedtime, fasted (no food ~2 h before), 5 nights a week; 12 weeks on, 4 off. Reconstitute the 10 mg vial with 3 mL BAC water (~1.67 mg/mL of each).
The ladder reads in mg per compound: 6 units = tesamorelin 0.1 · ipamorelin 0.1 mg, 12 units = 0.2 · 0.2 mg, 18 units = 0.3 · 0.3 mg — 18 units is ipamorelin's own top of range. A 0.3 mL (30-unit) insulin syringe makes the 6-unit start easier to read.
A vial already mixed at 2 mL draws 4 / 8 / 12 units for the same doses. Specific dosing varies by goal and physician guidance.
- How often
- 5 days on / 2 off
- When
- Bedtime · Fasted
- Route
- Subcutaneous
- Vial & water
- 10 mg in 3 mL · 6 units ≈ 0.1 mg Tesamorelin + 0.1 mg Ipamorelin
- Cycle
- 12 weeks on, 4 weeks off is a common pattern for growth-hormone secretagogue blends
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates pituitary GH release through the GHRH receptor; it is FDA-approved (as Egrifta) only for excess abdominal fat in HIV-associated lipodystrophy, where its trials gave 1–2 mg a day.
No study of this combination exists, and ipamorelin is not FDA-approved, so this is a research-context blend.
Ipamorelin is a pentapeptide ghrelin-receptor (GHS-R1a) agonist that, in rats and pigs, released GH without the ACTH or cortisol rise of older secretagogues; its human studies are intravenous, and there is no published under-the-skin dose-finding study. The two act on complementary receptors.
References6
- Falutz J et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation (AIDS) (dose-ranging: 1 or 2 mg daily)
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV (N Engl J Med) (2 mg daily, 26 weeks)
- Stanley TL et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men (J Clin Endocrinol Metab) (2 mg daily, healthy men)
- Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (Pharm Res) (IV only)
- Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (Int J Colorectal Dis) (IV, post-operative ileus)
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue (Eur J Endocrinol) (rat and pig)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.